中華銀科技(00515.HK)與戰略顧問就建議合作訂立合作框架協議
格隆匯3月27日丨中華銀科技(00515.HK)發佈公吿,2025年3月27日,公司與戰略顧問就建議合作訂立合作框架協議,涉及由戰略顧問轉介戰略投資者,旨在制定解決有關中國附屬公司現有貸款的建議。
有關中國附屬公司(即中山市達進及廣東達進)為於中國成立的有限公司。截至本公吿日期,(i)戰略顧問的註冊資本由廣州佳仁投資諮詢有限公司擁有90%權益,而廣州佳仁投資諮詢有限公司由龔華天擁有60%權益及由龍錦俊擁有40%權益;及(ii)戰略顧問及其最終實益擁有人均為獨立於公司或其關連人士且與彼等概無關連的第三方。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.